Search / Trial NCT06232122

Evaluation of 68Ga-FAPI-46 and 18F-FDG PET/CT Imaging for Detecting Recurrent Tumor Lesions in Patients of Ovarian Cancer

Launched by CHANG GUNG MEMORIAL HOSPITAL · Jan 20, 2024

Trial Information

Current as of October 08, 2024

Recruiting

Keywords

68 Ga Fapi 46 18 F Fdg Ca 125

Description

Ovarian cancer is the eighth most common cancer worldwide in females and usually diagnosed at an advanced stage. Serum cancer antigen 125 (CA125) is widely used in ovarian cancer. An elevation in CA125 levels can precede a clinically apparent recurrence by 3 to 6 months and 18F-FDG PET/CT can modify management in approximately half of these patients. However. 18F-FDG PET/CT may yield false negative results. 68Ga-FAPI-46 PET/CT shows potential here. This study is to assess the diagnostic performances of 68Ga-FAPI-46 and 18F-FDG PET/CT for ovarian cancer recurrence in patients with CA125 elev...

Gender

FEMALE

Eligibility criteria

  • Inclusion Criteria:
  • * Pathologically proven ovarian cancer with complete response after therapy
  • * Age between 30 and 80
  • * Elevation of serum CA125 value above the normal range (\>35 U/mL) or doubling of serum CA125 value within the normal range
  • * ECOG performance status grade 0 or 1 and willing to receive further therapy if disease recurrence is confirmed
  • * Willing to enter this prospective study with signed informed consent form
  • Exclusion Criteria:
  • * Patients with history of other malignancy
  • * Patients who are pregnant or lactating
  • * Patients with fasting fingerstick glucose level higher than 200 mg/dl
  • * Known allergic reactions to components of the radiopharmaceutical solutions for intravenous injection for 68Ga-FAPI-46 or 18F-FDG imaging studies
  • * Patients who are incapable of lying still for 30 minutes to receive the PET/CT scan as assessed by investigators

About Chang Gung Memorial Hospital

Chang Gung Memorial Hospital, one of the largest healthcare organizations in Taiwan, is renowned for its commitment to advancing medical research and improving patient care. As a clinical trial sponsor, the hospital leverages its extensive clinical expertise and state-of-the-art facilities to conduct innovative research across various medical disciplines. With a focus on collaboration and ethical practices, Chang Gung Memorial Hospital aims to contribute to the global body of medical knowledge through rigorous clinical trials that enhance treatment options and improve health outcomes for patients.

Locations

Taoyuan City, , Taiwan

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0